



NEWS RELEASE

CRINETICS PHARMACEUTICALS APPOINTS ANNE KLIBANSKI, M.D. TO SCIENTIFIC ADVISORY BOARD

2016-11-10

Crinetics Pharmaceuticals Appoints Anne Klibanski, M.D. to Scientific Advisory Board

November 10, 2016

| In **Press Releases**

| By **Joe DeMaegd**

SAN DIEGO – November 10, 2016 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on specialty endocrine disorders and endocrine-related cancers, announced today the addition of Anne Klibanski, M.D. as a member of the company’s scientific advisory board.

“I am excited to be a part of this growing team that is working to study and develop effective oral therapies for acromegaly and other neuroendocrine tumors,” said Dr. Klibanski. “The ultimate goal is to find treatments and cures for the wide range of neuroendocrine diseases and improve the lives of patients suffering from these serious conditions.”

“We continue to assemble a world-class team with expertise in creating and developing innovative therapeutics for specialty endocrine disorders,” said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. “We are excited to welcome Dr. Klibanski to the scientific advisory board of Crinetics Pharmaceuticals. She is an internationally-recognized leader in neuroendocrinology and complements our team as we grow Crinetics into a clinical-stage therapeutics company.”



Dr. Klibanski is the director of the Neuroendocrine and Pituitary Tumor Clinical Center and chief of the Neuroendocrine Unit at Massachusetts General Hospital, and the Laurie Carrol Guthart Professor of Medicine at Harvard Medical School. She is a clinical researcher who studies pituitary tumor pathogenesis and the impact that pituitary and hypothalamic disorders have on body composition, including low bone mass. Awards in recognition of her work have included The Endocrine Society Clinical Investigator Award and the British Trust Medal. She is the author of more than 350 peer-reviewed publications and has served on the NIH NIDDK Board of Counselors and on the Editorial Board of the Journal of Clinical Endocrinology and Metabolism. She is past-president of the Pituitary Society and serves on its board. She has been involved in leadership positions of many educational programs sponsored by the Endocrine Society, the Pituitary Society, and many patient advocacy groups to teach physicians and patients about pituitary tumors and neuroendocrine disorders. She has a B.A. from Barnard College and an M.D. from New York University School of Medicine.

ABOUT CRINETICS

PHARMACEUTICALS

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of specialty endocrine disorders and endocrine-related cancers. Its pioneering small molecule somatostatin agonist program for the treatment of acromegaly and neuroendocrine tumors aims to provide a convenient, more effective oral therapy for patients whose only current options are painful injected depot drugs. Crinetics was founded by a team of scientists with a proven track record of endocrine drug discovery and development to create important new therapeutic options for endocrinologists and their patients. The company is backed by top life sciences investors, 5AM Ventures, Versant Ventures, and Vivo Capital and is headquartered in San Diego.